Heather D. Turner - 16 Mar 2022 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Reporting relationship: Chief General Counsel
Issuer ticker: LYEL
Reported as of: 16 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Mar 2022, 16:11:11 UTC
Prior SEC filing: 16 Jun 2021
Next SEC filing: 19 Nov 2024
Source filing: View source filing
Reporting owner signature: /s/ Heather Turner

Key filing fact

Heather D. Turner filed Form 4 for Lyell Immunopharma, Inc. (LYEL) on 18 Mar 2022.

Key facts

This page summarizes Heather D. Turner's Form 4 filing for Lyell Immunopharma, Inc. (LYEL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Mar 2022, 16:11.

Change

Previous filing in this sequence was filed on 16 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LYEL transaction Derivative

Option (right to buy)

Award

Transaction value: $0
Shares: +300,000
Change %
Price: $0.000000
Shares after: 300,000
Date: 16 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 300,000
Exercise price: $5.98
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

12.5% of the option shares shall vest on August 9, 2022, with the remaining option shares to vest in equal monthly installments over the following forty-two months.